Deborah Minor

As drug development programs advance, the challenges they face evolve, but the cost of misalignment remains constant. Gaps in CMC can quietly derail timelines, strain resources, and introduce unnecessary risk at critical inflection points. Recognizing this reality, Drug Discovery Alliances (DDA) is expanding its CMC consulting network to provide deeper, more flexible support across every phase of R&D, from discovery through commercial launch. CMC Expertise When and Where It’s Needed Most CMC...

CMC is one of the most complex and high-impact areas of drug development. Decisions made early can influence timelines, cost structure, regulatory outcomes, and long-term manufacturing success. At Drug Discovery Alliances, CMC consultants support teams by bringing practical experience and strategic perspective during these critical stages. The Right Expertise at the Right Time As programs advance, many companies reach a point where deeper CMC expertise is required, but building a full...

How R&D and Manufacturing Leaders Can Prepare Now As we move toward 2026, the pharmaceutical and biotech landscape is shaped by rapid innovation, changing supply needs, and increasing pressure to deliver programs more efficiently. Organizations that understand these shifts early will be positioned to advance development timelines, reduce risk, and strengthen their competitive advantage. At DDA, we follow these trends closely to support our clients with informed and strategic guidance. 1....